CN110028549B - Antihypertensive peptide and antihypertensive protein and application thereof - Google Patents
Antihypertensive peptide and antihypertensive protein and application thereof Download PDFInfo
- Publication number
- CN110028549B CN110028549B CN201910339075.5A CN201910339075A CN110028549B CN 110028549 B CN110028549 B CN 110028549B CN 201910339075 A CN201910339075 A CN 201910339075A CN 110028549 B CN110028549 B CN 110028549B
- Authority
- CN
- China
- Prior art keywords
- antihypertensive
- peptide
- converting enzyme
- antihypertensive peptide
- angiotensin converting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003276 anti-hypertensive effect Effects 0.000 title claims abstract description 142
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 125
- 102000004169 proteins and genes Human genes 0.000 title abstract description 23
- 108090000623 proteins and genes Proteins 0.000 title abstract description 23
- 239000002220 antihypertensive agent Substances 0.000 claims abstract description 17
- 229940127088 antihypertensive drug Drugs 0.000 claims abstract description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 6
- 239000005541 ACE inhibitor Substances 0.000 claims description 9
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 9
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims description 6
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 5
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 abstract description 73
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 abstract description 72
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 abstract description 72
- 230000036772 blood pressure Effects 0.000 abstract description 29
- 230000000694 effects Effects 0.000 abstract description 13
- 230000036541 health Effects 0.000 abstract description 13
- 239000001257 hydrogen Substances 0.000 description 23
- 229910052739 hydrogen Inorganic materials 0.000 description 23
- 102000004196 processed proteins & peptides Human genes 0.000 description 22
- 150000001413 amino acids Chemical class 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 19
- 239000000047 product Substances 0.000 description 14
- 239000000463 material Substances 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 11
- 101800004538 Bradykinin Proteins 0.000 description 10
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 102400000967 Bradykinin Human genes 0.000 description 9
- 125000000539 amino acid group Chemical group 0.000 description 9
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 8
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 230000001077 hypotensive effect Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 102400000344 Angiotensin-1 Human genes 0.000 description 6
- 101800000734 Angiotensin-1 Proteins 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- 208000001953 Hypotension Diseases 0.000 description 6
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 208000021822 hypotensive Diseases 0.000 description 6
- 102400000345 Angiotensin-2 Human genes 0.000 description 5
- 101800000733 Angiotensin-2 Proteins 0.000 description 5
- MMFKFJORZBJVNF-UWVGGRQHSA-N His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 MMFKFJORZBJVNF-UWVGGRQHSA-N 0.000 description 5
- 108010007859 Lisinopril Proteins 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 229950006323 angiotensin ii Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000001631 hypertensive effect Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229960002394 lisinopril Drugs 0.000 description 5
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 108010025306 histidylleucine Proteins 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108010064733 Angiotensins Proteins 0.000 description 3
- 102000015427 Angiotensins Human genes 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000006664 bond formation reaction Methods 0.000 description 3
- -1 calcium antagonists Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229940090044 injection Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000003032 molecular docking Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- AAXWBCKQYLBQKY-IRXDYDNUSA-N (2s)-2-[[(2s)-2-[(2-benzamidoacetyl)amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)C=1C=CC=CC=1)C1=CN=CN1 AAXWBCKQYLBQKY-IRXDYDNUSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000269331 Ambystoma Species 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 108010016268 hippuryl-histidyl-leucine Proteins 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000007940 sugar coated tablet Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- HTIQEAQVCYTUBX-KRWDZBQOSA-N (S)-amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-KRWDZBQOSA-N 0.000 description 1
- KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- FHHHOYXPRDYHEZ-COXVUDFISA-N Alacepril Chemical group CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FHHHOYXPRDYHEZ-COXVUDFISA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- JOATXPAWOHTVSZ-UHFFFAOYSA-N Celiprolol Chemical compound CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(C(C)=O)=C1 JOATXPAWOHTVSZ-UHFFFAOYSA-N 0.000 description 1
- IFYLTXNCFVRALQ-OALUTQOASA-N Ceronapril Chemical compound O([C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)P(O)(=O)CCCCC1=CC=CC=C1 IFYLTXNCFVRALQ-OALUTQOASA-N 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 108010066671 Enalaprilat Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- RVKIPWVMZANZLI-UHFFFAOYSA-N H-Lys-Trp-OH Natural products C1=CC=C2C(CC(NC(=O)C(N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-UHFFFAOYSA-N 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 241000205573 Jeffersonia Species 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- WSXTWLJHTLRFLW-SRVKXCTJSA-N Lys-Ala-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O WSXTWLJHTLRFLW-SRVKXCTJSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 240000002624 Mespilus germanica Species 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- 108010087066 N2-tryptophyllysine Proteins 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- OZILORBBPKKGRI-RYUDHWBXSA-N Phe-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 OZILORBBPKKGRI-RYUDHWBXSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- CSZFFQBUTMGHAH-UAXMHLISSA-N Thr-Thr-Trp Chemical group C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N)O CSZFFQBUTMGHAH-UAXMHLISSA-N 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- MJXNDRCLGDSBBE-FHWLQOOXSA-N Val-His-Trp Chemical group CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)N MJXNDRCLGDSBBE-FHWLQOOXSA-N 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- CRROPKNGCGVIOG-QCOJBMJGSA-N [des-Phe(8), des-Arg(9)]-bradykinin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(O)=O)CCC1 CRROPKNGCGVIOG-QCOJBMJGSA-N 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229950007884 alacepril Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 229950010731 arotinolol Drugs 0.000 description 1
- BHIAIPWSVYSKJS-UHFFFAOYSA-N arotinolol Chemical compound S1C(SCC(O)CNC(C)(C)C)=NC(C=2SC(=CC=2)C(N)=O)=C1 BHIAIPWSVYSKJS-UHFFFAOYSA-N 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 229940038481 bee pollen Drugs 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002781 bisoprolol Drugs 0.000 description 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 229960002320 celiprolol Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229950005749 ceronapril Drugs 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 229960005025 cilazapril Drugs 0.000 description 1
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 229960005227 delapril Drugs 0.000 description 1
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960002680 enalaprilat Drugs 0.000 description 1
- LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 description 1
- ADFCQWZHKCXPAJ-GFCCVEGCSA-N equol Chemical compound C1=CC(O)=CC=C1[C@@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-GFCCVEGCSA-N 0.000 description 1
- 235000019126 equol Nutrition 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- 229960004340 lacidipine Drugs 0.000 description 1
- GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004294 lercanidipine Drugs 0.000 description 1
- ZDXUKAKRHYTAKV-UHFFFAOYSA-N lercanidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 description 1
- 229950008554 levamlodipine Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 229960000619 nebivolol Drugs 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical group COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960005366 nilvadipine Drugs 0.000 description 1
- 229960000227 nisoldipine Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- 108010018625 phenylalanylarginine Proteins 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- KEDYTOTWMPBSLG-HILJTLORSA-N ramiprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)C(O)=O)CC1=CC=CC=C1 KEDYTOTWMPBSLG-HILJTLORSA-N 0.000 description 1
- 229960002231 ramiprilat Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229960002909 spirapril Drugs 0.000 description 1
- HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 description 1
- 108700035424 spirapril Proteins 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 229960004084 temocapril Drugs 0.000 description 1
- FIQOFIRCTOWDOW-BJLQDIEVSA-N temocapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C[C@H](SC1)C=1SC=CC=1)=O)CC1=CC=CC=C1 FIQOFIRCTOWDOW-BJLQDIEVSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 229960002051 trandolapril Drugs 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a blood pressure lowering peptide and a blood pressure lowering protein and application thereof; the amino acid sequence of the antihypertensive peptide is VHW, and the amino acid sequence of the antihypertensive protein contains VHW; the antihypertensive peptide and the antihypertensive protein can inhibit the activity of angiotensin converting enzyme, thereby reducing blood pressure, and can be used for preparing various antihypertensive drugs or health products.
Description
Technical Field
The invention belongs to the technical field of food or medicine, and relates to antihypertensive peptides, antihypertensive proteins and application thereof.
Background
Angiotensin Converting Enzyme (ACE) is an enzyme that can cause an increase in blood pressure, and has the following two regulatory pathways.
First, angiotensin converting enzyme cleaves two amino acids (His-Leu) at the terminal of angiotensin I (angiotensinin I) to convert angiotensin I to angiotensin ii (angiotensinin ii). Wherein the amino acid sequence of the angiotensin I is Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu, which is DRVYIHPFHL for short. The amino acid sequence of angiotensin II is Asp-Arg-Val-Tyr-Ile-His-Pro-Phe, abbreviated as DRVYIHPF. Angiotensin II is a vasoconstrictor that promotes constriction of blood vessels, thereby increasing blood pressure.
Secondly, angiotensin converting enzyme can cut two amino acids (Phe-Arg) at the terminal of Bradykinin (Bradykinin) to inactivate the Bradykinin. Wherein the amino acid sequence of bradykinin is Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg, and the amino acid sequence of inactivated bradykinin is Arg-Pro-Pro-Gly-Phe-Ser-Pro. Bradykinin has the function of dilating blood vessels, but in its inactivated state, bradykinin loses its ability to dilate blood vessels, thereby increasing blood pressure.
ACE is a metallopeptidase containing a bound Zn 2+ This is the "essential binding site" to which the substrate binds. Zn 2+ The binding site is the site of the active group of the ACE-catalyzed reaction. The combined action of various ACE inhibitors is with Zn of ACE 2+ The binding sites bind and inactivate.
If angiotensin converting enzyme is inactivated, angiotensin converting enzyme cannot convert angiotensin I into angiotensin II, and blood vessels will not contract; at the same time, angiotensin converting enzyme does not inactivate bradykinin and the blood vessel is dilated. The combined action of the two can reduce blood pressure. Therefore, the search for a polypeptide or protein capable of inactivating angiotensin converting enzyme is a technical problem to be solved.
Disclosure of Invention
One of the objects of the present invention is to provide a hypotensive peptide capable of inhibiting angiotensin converting enzyme.
Another object of the present invention is to provide the use of the above-mentioned antihypertensive peptide.
In order to achieve the above purpose, the solution of the invention is as follows:
a antihypertensive peptide whose amino acid sequence is TTW is called a first antihypertensive peptide.
A hypotensive peptide having an amino acid sequence of VHW, referred to as a second hypotensive peptide.
The amino acid sequence of the antihypertensive peptide is shown as SEQ ID NO: 1, referred to as a third antihypertensive peptide.
Any of the above-mentioned antihypertensive peptides can be used as an angiotensin converting enzyme inhibitor.
Any one of the antihypertensive peptides can be used for preparing antihypertensive drugs.
Any one of the antihypertensive peptides can be used for preparing the antihypertensive health care product.
A blood pressure lowering protein comprising TTW, VHW and a sequence as set forth in SEQ ID NO: 1, or a pharmaceutically acceptable salt thereof.
The blood pressure lowering protein can be used as angiotensin converting enzyme inhibitor.
The blood pressure lowering protein can be used for preparing blood pressure lowering medicines.
The blood pressure lowering protein can be used for preparing blood pressure lowering health products.
Due to the adoption of the scheme, the invention has the beneficial effects that:
the antihypertensive peptide is obtained by screening hydrolysate of natural food, has obvious inhibitory activity on angiotensin converting enzyme, can be independently used for preparing antihypertensive drugs or antihypertensive health products, and can also be used in combination with the antihypertensive drugs in the prior art so as to obtain better synergistic antihypertensive effect.
Drawings
FIG. 1 is a schematic diagram showing hydrogen bond formation between a first antihypertensive peptide of the present invention and the active center of angiotensin-converting enzyme.
FIG. 2 is a schematic diagram showing hydrogen bond formation between a second antihypertensive peptide of the present invention and the active center of angiotensin-converting enzyme.
FIG. 3 is a schematic diagram showing hydrogen bond formation between a third antihypertensive peptide of the present invention and the active center of angiotensin-converting enzyme.
FIG. 4 is a graph showing the hypotensive effect of the antihypertensive peptides.
Detailed Description
The invention provides a plurality of antihypertensive peptides and application thereof.
< first antihypertensive peptide >
The invention provides a blood pressure lowering peptide which consists of three amino acids, wherein the amino acid sequence of the blood pressure lowering peptide is Thr-Thr-Trp, which is TTW for short. For the sake of convenience of explanation, the first antihypertensive peptide will be hereinafter collectively referred to. The amino acids in the present invention are all arranged from the N-terminus to the C-segment.
The molecular docking experiment shows that the first T in the first antihypertensive peptide forms 3 hydrogen bonds with Ala354 of the active center of Angiotensin Converting Enzyme (ACE); the second T in the first antihypertensive peptide forms a hydrogen bond with each of His353, Glu384 and His 513; w in the first antihypertensive peptide forms a hydrogen bond with Glu403, so the first antihypertensive peptide and Angiotensin Converting Enzyme (ACE) together form 7 hydrogen bonds. The formation of these 7 hydrogen bonds is shown in FIG. 1. The amino acids in the circle represent the amino acid sequence in ACE, and the middle chain is the configuration formed by the sequence of the antihypertensive peptide in ACE.
These amino acid residues are important amino acid residues in the active center of Angiotensin Converting Enzyme (ACE), and have an important effect on the activity of ACE. When the first antihypertensive peptide forms a hydrogen bond with these amino acid residues of the active center of Angiotensin Converting Enzyme (ACE), the active center of Angiotensin Converting Enzyme (ACE) is no longer able to bind angiotensin, and the Angiotensin Converting Enzyme (ACE) is inactivated, and thus, the first antihypertensive peptide can act as an angiotensin converting enzyme inhibitor.
< use of the first antihypertensive peptide >
1. The first antihypertensive peptide can be used for preparing antihypertensive drugs.
The first antihypertensive peptide of the present invention can be used alone as an antihypertensive drug, and in this case, the first antihypertensive peptide is used in combination with an auxiliary material to prepare a pharmaceutical granule, a capsule, a tablet (e.g., a sugar-coated tablet or a film-coated tablet), a pill, an oral liquid, an injection, or the like.
When the first antihypertensive peptide is used as a pharmaceutical granule, the excipient may be maltodextrin and/or vanillin.
When the first antihypertensive peptide is used as a sugar-coated tablet, the excipient may be starch and/or magnesium stearate.
When the first antihypertensive peptide is prepared into oral liquid for use, the auxiliary materials can be sodium benzoate, aspartame, acesulfame potassium, essence and purified water.
When the first antihypertensive peptide is used as an injection, the excipient may be mannitol, sodium dihydrogen phosphate and/or disodium hydrogen phosphate. The injection can be prepared into 0.9% sodium chloride injection or 5% glucose injection and then is instilled intravenously or injected intramuscularly.
The first antihypertensive peptide can also be used in combination with antihypertensive drugs in the prior art so as to obtain better synergistic antihypertensive effect.
The blood pressure lowering drugs in the prior art include beta-blockers, calcium antagonists, ACE inhibitors, diuretics, and the like.
Wherein the beta blocker is selected from nebivolol, pralol, arotinolol, atenolol, celiprolol, carvedilol, labetalol, bisoprolol.
The calcium antagonist is selected from nifedipine, amlodipine (including levamlodipine), lercanidipine, felodipine, nilvadipine, lacidipine, and nisoldipine.
The ACE inhibitor is selected from the group consisting of alacepril, benazepril, captopril, ceronapril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, lisinopril, ramipril, ramiprilat, perindopril, quinapril, spirapril, temocapril, trandolapril.
The diuretic is selected from hydrochlorothiazide and trichlorothiazide.
2. The first antihypertensive peptide can be used for preparing antihypertensive health products.
The first antihypertensive peptide of the invention can be prepared into the antihypertensive health product by adding auxiliary materials, wherein the auxiliary materials can comprise: any one or more of starch, gelatin, titanium dioxide, whey protein, sucrose, vitamin E, glutathione, arginine, citrulline, dietary fiber, collagen, cephalin, cellulose, glucose, xylose, honey, lecithin, carotine, vitamin B1, vitamin B2, vitamin C, ferrum, calcium, bee pollen, black fungus powder (200 plus 500 meshes), mushroom powder (300 plus 500 meshes), lucid ganoderma powder (300 plus 500 meshes), konjak powder (300 plus 500 meshes), astragalus powder (200 plus 500 meshes), medlar powder (200 plus 500 meshes) and ginseng powder (500 plus 1000 meshes).
< second antihypertensive peptide >
The invention provides a hypotensive peptide which consists of three amino acids, wherein the amino acid sequence of the hypotensive peptide is Val-His-Trp, which is abbreviated as VHW. For the sake of convenience of explanation, the second antihypertensive peptide will be hereinafter collectively referred to.
The molecular docking experiment shows that V in the second antihypertensive peptide and Glu411 of the active center of Angiotensin Converting Enzyme (ACE) form 2 hydrogen bonds; h in the second antihypertensive peptide forms a hydrogen bond with Ala354, His353 and Glu384 respectively; w in the second antihypertensive peptide forms a hydrogen bond with Tyr520, so that the second antihypertensive peptide and Angiotensin Converting Enzyme (ACE) together form 7 hydrogen bonds. The formation of these 7 hydrogen bonds is shown in FIG. 2.
These amino acid residues are also important amino acid residues in the active center of Angiotensin Converting Enzyme (ACE), and have an important effect on the activity of ACE. When the second antihypertensive peptide forms a hydrogen bond with these amino acid residues of the active center of Angiotensin Converting Enzyme (ACE), the active center of Angiotensin Converting Enzyme (ACE) is no longer able to bind angiotensin, and the Angiotensin Converting Enzyme (ACE) is inactivated, and thus, the second antihypertensive peptide can also act as an angiotensin converting enzyme inhibitor.
< use of the second antihypertensive peptide >
1. The second antihypertensive peptide can be used for preparing antihypertensive drugs.
2. The second antihypertensive peptide can be used for preparing antihypertensive health products.
When the second antihypertensive peptide is used for preparing the antihypertensive drug or the antihypertensive health product, the first antihypertensive peptide can be referred to as an auxiliary material which can be used in combination with the second antihypertensive peptide.
< third antihypertensive peptide >
The invention provides a antihypertensive peptide, the amino acid sequence of which is shown as SEQ ID NO: 1 is shown. For the sake of convenience of explanation, the third antihypertensive peptide will be hereinafter collectively referred to. The third antihypertensive peptide consists of four amino acids, and the amino acid sequence of the third antihypertensive peptide is Lys-Ala-Lys-Trp, which is abbreviated as KAKW.
Molecular docking shows that the first K in the third antihypertensive peptide forms two hydrogen bonds with Ala356 of the ACE active center and one hydrogen bond with Glu 411; w in the third antihypertensive peptide forms 2 hydrogen bonds with Gln281 and forms one hydrogen bond with Tyr520 and Asp415 respectively; the second K in the third antihypertensive peptide forms a hydrogen bond with His353, Lys511 respectively, so that the third antihypertensive peptide and Angiotensin Converting Enzyme (ACE) together form 9 hydrogen bonds. The formation of these 9 hydrogen bonds is shown in FIG. 3. These amino acid residues are important amino acid residues in the active center of Angiotensin Converting Enzyme (ACE), and have an important effect on the activity of ACE. When the third antihypertensive peptide forms a hydrogen bond with these amino acid residues of the active center of Angiotensin Converting Enzyme (ACE), the active center of Angiotensin Converting Enzyme (ACE) can no longer bind angiotensin, and thus Angiotensin Converting Enzyme (ACE) is inactivated, and thus, the third antihypertensive peptide can be used as an angiotensin converting enzyme inhibitor.
< use of third antihypertensive peptide >
1. The third antihypertensive peptide can be used for preparing antihypertensive drugs.
2. The third antihypertensive peptide can be used for preparing antihypertensive health products.
When the third antihypertensive peptide is used for preparing the antihypertensive drug or the antihypertensive health product, the first antihypertensive peptide can be referred to as an auxiliary material which can be used in combination with the third antihypertensive peptide.
< blood pressure-lowering protein >
A blood pressure lowering protein characterized by: it contains TTW, VHW and the amino acid sequence as set forth in SEQ ID NO: 1, or a pharmaceutically acceptable salt thereof.
The above polypeptides and proteins can be synthesized by artificial methods, and thus the synthesis methods are not described in detail.
< use of hypotensive protein >
1. The blood pressure lowering protein can be used for preparing blood pressure lowering medicines.
2. The blood pressure lowering protein can be used for preparing blood pressure lowering health products.
When the antihypertensive protein is used for preparing the antihypertensive drug or the antihypertensive health care product, the first antihypertensive peptide can be referred to as an auxiliary material which can be matched with the antihypertensive protein for use.
The blood pressure lowering activity of various blood pressure lowering peptides and the like will be described below with reference to experiments.
< experiment 1: experiment of in vitro inhibition of angiotensin converting enzyme by various antihypertensive peptides >
The various antihypertensive peptides of the present invention are competitive inhibitors having a strong affinity for the active region of angiotensin converting enzyme, have a higher affinity for the active region than angiotensin I or bradykinin, and are not easily released from the binding region once bound, and thus can reduce the activity of the active region of angiotensin converting enzyme, even inactivate it, thereby preventing angiotensin converting enzyme from converting angiotensin I to angiotensin II and preventing angiotensin converting enzyme from inactivating bradykinin, and thus lowering blood pressure. The inhibitory ability of various antihypertensive peptides against angiotensin converting enzyme was verified by experiments as follows.
The determination principle of this experiment is as follows:
hippurylhistidyl leucine (Hip-His-Leu, HHL for short) can serve as a substrate for Angiotensin Converting Enzyme (ACE) and is hydrolyzed to hippuric acid and His-Leu. The inhibitor can inhibit the ability of the angiotensin converting enzyme to catalyze and hydrolyze the equol histidyl leucine, so that the content of the hippuric acid in the product is reduced, and therefore, the inhibition rate of the inhibitor on the angiotensin converting enzyme can be calculated by detecting the content of the hippuric acid in the product.
The assay procedure for this experiment was as follows:
(1) taking a plurality of EP tubes as reaction containers, adding 20 mu L of deionized water into the EP tube of the control group, and adding 20 mu L of samples to be detected with different concentrations into the EP tube of the experimental group;
(2) 80 μ L of 5M equacy histidyl leucine (HHL) was added to each EP tube and water-bathed at 37 ℃ for 5 min;
(3) adding 10mU L of 310mU/mL Angiotensin Converting Enzyme (ACE) into each EP tube, and carrying out water bath at 37 ℃ for 5min to start the reaction;
(4) when the reaction is complete, adding 400 mu L of M HCL into each EP tube to terminate the reaction;
(5) filtering the reaction liquid in each EP tube by using a filter membrane with the diameter of 0.22 mu m, and storing the filtered liquid in a corresponding liquid phase vial;
(6) and carrying out high performance liquid chromatography detection on the liquid in each liquid phase small bottle, wherein the detection conditions are as follows: and (3) chromatographic column: thermo BDSHYPERSIL C18(250 mm. times.3 mm. times.5 μm); column temperature: 30 ℃; flow rate: 0.8 mL/min; detection wavelength: 228 nm; sample introduction amount: 10mu L of the solution; mobile phase A: ultrapure water (0.1% trifluoroacetic acid TFA); mobile phase B: acetonitrile; the elution conditions are shown in Table 1.
TABLE 1 elution conditions for high performance liquid chromatography
(7) The method for calculating the inhibition rate of each sample to be tested on the angiotensin converting enzyme comprises the following steps:
x ═ a control-a)/a control
In the formula: X-ACE inhibition (%);
control-peak area of control;
a-peak area of experimental group.
(8) Calculation of IC50 of the test sample:
and (3) drawing by taking the concentration of the sample to be detected as an abscissa and the ACE inhibition rate as an ordinate to obtain an inhibition rate-sample concentration relation curve, and obtaining the concentration of the sample to be detected when the inhibition rate reaches 50% through the curve, namely the IC50 of the sample to be detected.
Wherein the sample to be tested is a sample containing a first antihypertensive peptide, a second antihypertensive peptide, a third antihypertensive peptide or an antihypertensive protein.
The IC50 of the test samples is shown in table 2.
TABLE 2 IC50 for samples tested
Antihypertensive peptides | IC 50 (μM) |
First antihypertensive peptide (TTW) | 0.61 |
Second antihypertensive peptide (VHW) | 0.91 |
Third antihypertensive peptide (KAKW) | 2.02 |
The detection results show that the three antihypertensive peptides have obvious effect of inhibiting angiotensin converting enzyme in an in-vitro angiotensin converting enzyme inhibiting experiment, and the inhibition effect of the antihypertensive peptides is close to the in-vitro inhibition effect of lisinopril which is a classical medicine for treating hypertension (IC50 is 0.0214 mu M).
< experiment 2: experiment of in vivo inhibition of angiotensin converting enzyme by various antihypertensive peptides >
The experiment mainly verifies the influence of various antihypertensive peptides on the blood pressure of a hypertensive rat, and comprises the following steps:
(1) spontaneous hypertensive rats (SHRs, 10 weeks in size, male, weight 250-320g) were obtained with blood pressure above 180mmHg and purchased from Shanghaisi Leike animal laboratories;
(2) 6 hypertensive rats are raised in a group, and are circularly illuminated at the temperature of 22 +/-2 ℃ for 12 hours to supply food and drinking water;
(3) dissolving different antihypertensive peptides in physiological saline, calculating the amount of the physiological saline according to 3 mu mol/Kg of each hypertensive rat in an experimental group, performing intragastric administration on the physiological saline according to the amount of 1ml/100g of the weight of the rat, and performing intragastric administration on a control group by using the physiological saline with the same dose and feeding the antihypertensive drug lisinopril;
(4) after gavage, the blood pressure of these hypertensive rats was measured at 0h, 1h, 2h, 4h, 6h and 8h, respectively. All results were measured in triplicate.
The results are shown in FIG. 4. As can be seen from fig. 4, the blood pressure of the three antihypertensive peptides is significantly decreased compared to the control group, indicating that the three antihypertensive peptides have an antihypertensive effect in vivo, and the antihypertensive effect of the three antihypertensive peptides is considered to be better than that of lisinopril in the early stage, compared to lisinopril group.
In conclusion, the antihypertensive peptide not only has better in-vitro antihypertensive activity, but also has good in-vivo activity after being digested and absorbed by gastrointestinal tract, and the antihypertensive function of the antihypertensive peptide is not lost.
The present invention will be further described with reference to the following examples.
Example 1: antihypertensive drug tablet
The antihypertensive drug tablet of this example contains 5 wt% of antihypertensive peptide and 95 wt% of auxiliary materials. The antihypertensive peptide is the first antihypertensive peptide, and the auxiliary materials are starch and magnesium stearate.
In fact, the antihypertensive peptide may be any one or more of the second antihypertensive peptide, the third antihypertensive peptide, and the antihypertensive protein. The adjuvant can be any one or more of starch, sucrose and maltodextrin. The content of the antihypertensive peptide may be 1 to 20 wt% and the content of the auxiliary material may be 80 to 99 wt%.
Example 2: health product for reducing blood pressure
The antihypertensive drug tablet of this example contains 15 wt% of antihypertensive peptide and 85 wt% of auxiliary materials. The antihypertensive peptide is the third antihypertensive peptide, and the auxiliary materials are starch, honey, dietary fiber, arginine and glutathione.
Wherein, the antihypertensive peptide can be any one or more of the first antihypertensive peptide, the second antihypertensive peptide and the antihypertensive protein. The content of the antihypertensive peptide may be 1 to 20 wt% and the content of the auxiliary material may be 80 to 99 wt%.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. It will be readily apparent to those skilled in the art that various modifications to these embodiments may be made, and the generic principles described herein may be applied to other embodiments without the use of the inventive faculty. Therefore, the present invention is not limited to the above embodiments, and those skilled in the art should make improvements and modifications within the scope of the present invention based on the disclosure of the present invention.
Sequence listing
<110> university of east China's college of science
<120> antihypertensive peptides and antihypertensive proteins, and use thereof
<130> 191033
<141> 2019-04-25
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 4
<212> PRT
<213> Natural food (2 Ambystoma latex x Ambystoma jeffersonia)
<400> 1
Lys Ala Lys Trp
1
Claims (4)
1. The application of the antihypertensive peptide in preparing the angiotensin converting enzyme inhibitor is characterized in that the amino acid sequence of the antihypertensive peptide is VHW.
2. The application of the antihypertensive peptide in preparing the antihypertensive drug is characterized in that the amino acid sequence of the antihypertensive peptide is VHW.
3. The application of the antihypertensive peptide in preparing the antihypertensive health-care product is characterized in that the amino acid sequence of the antihypertensive peptide is VHW.
4. The application of the antihypertensive peptide in preparing the antihypertensive food is characterized in that the amino acid sequence of the antihypertensive peptide is VHW.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910339075.5A CN110028549B (en) | 2016-07-07 | 2016-07-07 | Antihypertensive peptide and antihypertensive protein and application thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610529516.4A CN106188227B (en) | 2016-07-07 | 2016-07-07 | Blood pressure lowering peptide and blood pressure lowering protein and its application |
CN201910339075.5A CN110028549B (en) | 2016-07-07 | 2016-07-07 | Antihypertensive peptide and antihypertensive protein and application thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610529516.4A Division CN106188227B (en) | 2016-07-07 | 2016-07-07 | Blood pressure lowering peptide and blood pressure lowering protein and its application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110028549A CN110028549A (en) | 2019-07-19 |
CN110028549B true CN110028549B (en) | 2022-08-05 |
Family
ID=57465593
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610529516.4A Active CN106188227B (en) | 2016-07-07 | 2016-07-07 | Blood pressure lowering peptide and blood pressure lowering protein and its application |
CN201910338676.4A Active CN110028550B (en) | 2016-07-07 | 2016-07-07 | Antihypertensive peptide and antihypertensive protein and application thereof |
CN201910339075.5A Active CN110028549B (en) | 2016-07-07 | 2016-07-07 | Antihypertensive peptide and antihypertensive protein and application thereof |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610529516.4A Active CN106188227B (en) | 2016-07-07 | 2016-07-07 | Blood pressure lowering peptide and blood pressure lowering protein and its application |
CN201910338676.4A Active CN110028550B (en) | 2016-07-07 | 2016-07-07 | Antihypertensive peptide and antihypertensive protein and application thereof |
Country Status (2)
Country | Link |
---|---|
CN (3) | CN106188227B (en) |
WO (1) | WO2018006667A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106188227B (en) * | 2016-07-07 | 2019-09-24 | 华东理工大学 | Blood pressure lowering peptide and blood pressure lowering protein and its application |
CN107007812A (en) * | 2017-04-05 | 2017-08-04 | 江苏大学 | A kind of method for extending captopril hypotensive efficacy time |
CN109206479B (en) * | 2017-09-18 | 2021-10-29 | 北京中医药大学 | Vinegar bean gluten source antihypertensive peptide and application thereof |
CN108892710B (en) * | 2018-07-24 | 2021-10-29 | 中国科学院海洋研究所 | Asparagus antihypertensive peptide extract, asparagus antihypertensive peptide and application of asparagus antihypertensive peptide extract and asparagus antihypertensive peptide |
CN111548387B (en) * | 2020-03-31 | 2020-12-18 | 华南农业大学 | Oligopeptide with blood pressure reducing effect and preparation method and application thereof |
CN113087767B (en) * | 2021-04-13 | 2022-04-05 | 江西师范大学 | Tripeptide RFY with blood pressure reducing function and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1872802A (en) * | 1998-02-19 | 2002-04-18 | Xcyte Therapies, Inc. | Compositions and methods for regulating lymphocyte activation |
WO2007117444A2 (en) * | 2006-03-31 | 2007-10-18 | Yinghe Hu | Protein detection by aptamers |
CN101153055A (en) * | 2007-08-17 | 2008-04-02 | 华东理工大学 | Novel peptide with angiotonin transferase restraining liveness and method of producing the same |
JPWO2010024293A1 (en) * | 2008-08-27 | 2012-01-26 | 塩野義製薬株式会社 | Set of anti-vasohibin monoclonal antibodies |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2782142B2 (en) * | 1992-07-23 | 1998-07-30 | カルピス株式会社 | Angiotensin converting enzyme inhibitor and method for producing the same |
JP3087575B2 (en) * | 1994-07-29 | 2000-09-11 | トヨタ自動車株式会社 | Heptaprenyl diphosphate synthase and DNA encoding the same |
GB9606040D0 (en) * | 1996-03-22 | 1996-05-22 | Isis Innovation | Active peptide |
AU1872902A (en) * | 1998-02-19 | 2002-04-18 | Xcyte Therapies, Inc. | Compositions and methods for regulating lymphocyte activation |
JP2003089700A (en) * | 2001-09-18 | 2003-03-28 | Life Science Management:Kk | Peptide |
TWI411441B (en) * | 2003-03-18 | 2013-10-11 | Suntory Holdings Ltd | Angiotensin-converting enzyme inhibitory peptides |
CN1908009B (en) * | 2004-12-29 | 2010-09-08 | 山东大学 | Acetes chinensis protein antigypertensive peptide and preparation method and application thereof |
US7179793B2 (en) * | 2005-02-14 | 2007-02-20 | Ocean Nutrition Canada Limited | Anti-hypertensive dietary supplement |
EP1874329B1 (en) * | 2005-04-28 | 2009-07-15 | DSMIP Assets B.V. | Blood pressure lowering protein hydrolysates |
CN101768209B (en) * | 2009-01-05 | 2011-08-31 | 北京林业大学 | Hypotensive peptide with high in-vivo activity and preparation and purification method thereof |
CN101906135A (en) * | 2010-07-27 | 2010-12-08 | 鲁军 | Novel spirulina source antihypertensive peptide and preparation method thereof |
CN102190706B (en) * | 2011-04-07 | 2013-06-12 | 江苏省农业科学院 | Loach protein antihypertensive peptide and preparation method thereof |
CN102586375A (en) * | 2012-02-24 | 2012-07-18 | 华东理工大学 | Application of pistacia vera L. in preparation ACE (Angiotensin Converting Enzyme) inhibitor |
CN102643348B (en) * | 2012-04-17 | 2014-07-02 | 中国医学科学院医学生物学研究所 | Recombinant chimeric protein carrying rotavirus antigen epitope and preparation thereof |
WO2014134225A2 (en) * | 2013-02-26 | 2014-09-04 | Pronutria, Inc. | Nutritive polypeptides, formulations and methods for treating disease and improving muscle health and maintenance |
CN103172698B (en) * | 2013-04-10 | 2015-02-18 | 华东理工大学 | Antihypertensive polypeptides |
CN104611411A (en) * | 2014-10-11 | 2015-05-13 | 浙江大学 | Screening method for clostridium butyricum producing efficient antibacterial peptide butyrisin |
CN106188227B (en) * | 2016-07-07 | 2019-09-24 | 华东理工大学 | Blood pressure lowering peptide and blood pressure lowering protein and its application |
-
2016
- 2016-07-07 CN CN201610529516.4A patent/CN106188227B/en active Active
- 2016-07-07 CN CN201910338676.4A patent/CN110028550B/en active Active
- 2016-07-07 CN CN201910339075.5A patent/CN110028549B/en active Active
-
2017
- 2017-05-27 WO PCT/CN2017/086294 patent/WO2018006667A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1872802A (en) * | 1998-02-19 | 2002-04-18 | Xcyte Therapies, Inc. | Compositions and methods for regulating lymphocyte activation |
WO2007117444A2 (en) * | 2006-03-31 | 2007-10-18 | Yinghe Hu | Protein detection by aptamers |
CN101153055A (en) * | 2007-08-17 | 2008-04-02 | 华东理工大学 | Novel peptide with angiotonin transferase restraining liveness and method of producing the same |
JPWO2010024293A1 (en) * | 2008-08-27 | 2012-01-26 | 塩野義製薬株式会社 | Set of anti-vasohibin monoclonal antibodies |
Non-Patent Citations (3)
Title |
---|
Antihypertensive Effects, Molecular Docking Study, and Isothermal Titration Calorimetry Assay of Angiotensin I‑Converting Enzyme Inhibitory Peptides from Chlorella vulgaris;Jingli Xie等;《J. Agric. Food Chem.》;20180118;第66卷;第1359-1368页 * |
Considerations for Docking of Selective Angiotensin-Converting Enzyme Inhibitors;Julio Caballero;《Molecules》;20200111;第25卷(第295期);第1-19页 * |
食源性血管紧张素转化酶抑制肽的抑制机理及体内降血压活性的研究;陈绪军;《中国优秀硕士论文全文数据库 工程科技I辑》;20210115(第1期);摘要 * |
Also Published As
Publication number | Publication date |
---|---|
CN110028550B (en) | 2022-08-05 |
CN106188227A (en) | 2016-12-07 |
CN110028550A (en) | 2019-07-19 |
CN110028549A (en) | 2019-07-19 |
CN106188227B (en) | 2019-09-24 |
WO2018006667A1 (en) | 2018-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110028549B (en) | Antihypertensive peptide and antihypertensive protein and application thereof | |
TWI411441B (en) | Angiotensin-converting enzyme inhibitory peptides | |
ES2286398T3 (en) | USE OF AT LEAST ONE PEPTIDE OF THE CASEINA "ALPHA S2" WITH INHIBITING ACTIVITY OF I'ACE FOR THE PREPARATION OF MEDICINES AND FOODS. | |
CN108840909B (en) | Porphyra antihypertensive peptide, porphyra antihypertensive peptide extract and application | |
JP5416964B2 (en) | Novel tripeptides, methods for producing these tripeptides, and methods for producing angiotensin converting enzyme inhibitors | |
JP2013071897A (en) | Method for producing angiotensin converting enzyme-inhibitory hypotensive peptide composition | |
US20150183822A1 (en) | Angiotensin-converting-enzyme inhibiting dipeptide | |
JPH04275298A (en) | Peptide and angiotensinase inhibitor containing the peptide as active component | |
JP5456144B1 (en) | Angiotensin converting enzyme inhibitory dipeptide | |
CN107586316B (en) | Polypeptides having thrombolytic activity | |
JPH07119234B2 (en) | Tripeptide | |
JPH03284694A (en) | New tripeptide and hypotensor | |
JPH03197491A (en) | Tripeptide | |
JPH0363295A (en) | Tripeptide | |
JPH0236195A (en) | Novel peptide and angiotensin converting enzyme inhibitor | |
JPH0778077B2 (en) | New peptide | |
CN102477078A (en) | Preparation of thymic humoral factor (THF)-gamma2 structure modified peptide and application of pharmaceutical composition thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |